Business
CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15 million
CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15
About this update from Crossject Sa
[{"type":"text","content":"Provides immediate new financing to support the Company’s next strategic milestones Strengthens shareholders’ equity and improves the Company’s financial structure Supports the continuation of ZEPIZURE® regulatory activities, including upcoming EUA-related steps, and the ramp-up of production readiness throughout 2026 May provide additional funding upon exercise of the warrantsTotal subscription price of €2.33 per unit, including approximately €1.704 for the share component and €0.626 for the warrant componentDIJON, FRANCE, May 22, 2026 – 07h30 (CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, currently in the advanced stages of development and registration for ZEPIZURE®, an injectable for the management of epileptic seizures, today announces the successful completion of a capital increase (the “Capital Increase”) reserved for a specific category of investors in the amount of 15 million euros through the issuance of 6,441,300 shares with a par value of 0.10 euros per share (the “New Shares”), representing 10.8% of its share capital, at a subscription price of 1.704 euro per share, and the issuance of 6,441,300 stock subscription warrants (the “Stock Subscription Warrants”) subscribed at a price of 0.626 euro per Stock Subscription Warrant (the “Stock Subscription Warrant Issuance” and, together with the Capital Increase, the “Transaction”). Four Stock Subscription Warrants entitle the holder to subscribe for five common shares upon payment of an exercise price of 2.68 euros per common share. The total number of common shares that may be subscribed for upon exercise of the 6,441,300 Stock Subscription Warrants is 8,051,625 common shares.Purpose of the Offering and Use of ProceedsThe net proceeds of the issuances will be used primarily (i) to fund the Company’s general corporate needs and extend its cash runway, (ii) to continue the regulatory development activities relating to ZEPIZURE®, in particular in view of the next steps associated with the EUA process,(iii) to pursue the investments and preparatory work required to ramp up industrial capacity, and (iv) &nb...